Citations

Showing 10 of 108135 citations.

Nodal and distant metastases in sinonasal mucosal melanoma: A population‐based analysis
Low, Christopher M. , Moore, Eric J. , Stokken, Janalee K., Abel, Kathryn M. Van , Janus, Jeffrey R. , Van Abel, Kathryn M , Choby, Garret , Price, Daniel L. , Choby, Garret

Mayo Clinic

The Laryngoscope | May 11, 2019 | Volume: 130 | Issue: 3 | Pages: 622-627

10.1002/lary.28065 | PMID 31077407 Get It

Objectives/HypothesisSinonasal mucosal melanoma (SNMM) is a rare malignant neoplasm. No study to date has analyzed the impact that nodal metastases and distant metastases at diagnosis have on overall survival (OS) and disease‐specific survival (DSS).Study DesignRetrospective database review.MethodsThe Surveillance, Epidemiology, and End Results database was queried for cases of SNMM. Descriptive statistics were used analyze patient demographic and clinicopathologic variables. The Kaplan‐Meier model was used to analyze survival, and the Cox proportional hazards model was used for multivariate analysis.ResultsThree hundred twenty‐eight cases of SNMM were identified. The most frequent sinonasal anatomic location was the nasal cavity in 279 (73.0%) patients, followed by the maxillary sinus in 60 (15.7%) patients. Regional nodal metastases at diagnosis occurred in 33 (8.6%) patients, whereas distant metastases at diagnosis occurred in 41 (10.7%) patients. Five‐year OS was 22.7%, and 5‐year DSS was 26.8%. The presence of positive nodes at diagnosis (OS P < .0001, DSS P < .0001), distant metastases at diagnosis (OS P = .0442, DSS P = .0442), primary tumor site (OS P < .0001, DSS P < .0001), and increasing age (OS P = .0012, DSS P = .0016) were found to be significant as negative predictors of OS and DSS.ConclusionsSNMM is a rare pathologic entity with a poor prognosis. The presence of nodal and distant metastases at diagnosis are negative prognostic factors in OS and DSS. These factors can be used in the development of new models of risk stratification and to inform treatment strategies and surveillance patterns.Level of EvidenceNALaryngoscope, 130:622–627, 2020
A novel phosphoglucomutase‐deficient mouse model reveals aberrant glycosylation and early embryonic lethality
Balakrishnan, Bijina, Verheijen, Jan , Lupo, Arielle, Raymond, Kimiyo , Turgeon, Coleman , Yang, Yueqin, Carter, Kandis L., Whitehead, Kevin J. , Lai, Kent , Kozicz, Tamás , Morava, Éva

Mayo Clinic

Journal of Inherited Metabolic Disease | May 11, 2019 | Volume: 42 | Issue: 5 | Pages: 998-1007

10.1002/jimd.12110 | PMID 31077402 Get It

AbstractPatients with phosphoglucomutase (PGM1) deficiency, a congenital disorder of glycosylation (CDG) suffer from multiple disease phenotypes. Midline cleft defects are present at birth. Overtime, additional clinical phenotypes, which include severe hypoglycemia, hepatopathy, growth retardation, hormonal deficiencies, hemostatic anomalies, frequently lethal, early‐onset of dilated cardiomyopathy and myopathy emerge, reflecting the central roles of the enzyme in (glycogen) metabolism and glycosylation. To delineate the pathophysiology of the tissue‐specific disease phenotypes, we constructed a constitutive Pgm2 (mouse ortholog of human PGM1)‐knockout (KO) mouse model using CRISPR‐Cas9 technology. After multiple crosses between heterozygous parents, we were unable to identify homozygous life births in 78 newborn pups (P = 1.59897E‐06), suggesting an embryonic lethality phenotype in the homozygotes. Ultrasound studies of the course of pregnancy confirmed Pgm2‐deficient pups succumb before E9.5. Oral galactose supplementation (9 mg/mL drinking water) did not rescue the lethality. Biochemical studies of tissues and skin fibroblasts harvested from heterozygous animals confirmed reduced Pgm2 enzyme activity and abundance, but no change in glycogen content. However, glycomics analyses in serum revealed an abnormal glycosylation pattern in the Pgm2+/− animals, similar to that seen in PGM1‐CDG.
Systematic Appraisal of the American College of Rheumatology Clinical Practice Guidelines
Duarte‐García, Alí , Cavalcante, Milena, Arabelovic, Senada, Wong, John B. , Duarte-García, Alí

Mayo Clinic

ACR Open Rheumatology | May 11, 2019 | Volume: 1 | Issue: 3 | Pages: 188-193

10.1002/acr2.1027 | PMID 31777794 Get It

ObjectiveBecause the American College of Rheumatology (ACR) practice guidelines affect the United States' and international treatment practice, we used the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument to characterize the quality of the guidelines and to identify potential areas for improvement.MethodsUsing the six quality domains in the AGREE II online tool, four reviewers assessed the practice guidelines available at the ACR website and the immediately previous version to summarize the domain scores for each guideline and examine trends over time.ResultsAs of April 2016, the ACR website listed nine guidelines, four with immediate previous versions. Based on AGREE II, the minimum and maximum for each domain (with higher being better) of the current guidelines were 78‐99 for Scope and Purpose, 57‐99 for Stakeholder Involvement, 87‐ 96 for Rigor of the Methodology, 83‐99 for Clarity of Presentation, 49‐78 for Applicability, 69‐85 for Editorial Independence, and 71‐96 overall. Over time, although the average domain quality of the guidelines improved for all, the Applicability and Editorial Independence domains had the least amount of improvement. For the four guidelines with previous versions, the mean (SD) absolute improvements for each domain were 18 (±11) for Scope and Purpose, 13 (±8) for Stakeholder Involvement, 38 (±22) for Rigor of the Methodology, 25 (±15) for Clarity of Presentation, 22 (±12) for Applicability, 24 (±17) for Editorial Independence, and 31 (±5) overall.ConclusionBased on the AGREE II instrument, the ACR guidelines have achieved high quality over the past 16 years. The Applicability and Editorial Independence domains have the greatest potential for future improvement.
Combined bipedicled latissimus dorsi and groin flap for anterior chest wall reconstruction
Boonipat, Thanapoom , Ji, Lou, Manrique, Oscar J. , Ji, Lou, Chen, Hung‐Chi

Mayo Clinic

BMJ Case Reports | May 11, 2019 | Volume: 12 | Issue: 5 | Pages: e227372

10.1136/bcr-2018-227372 | PMID 31079037 Get It

We provide a case report of reconstruction of a massive chest wall defect after recurrent phyllodes tumour resections. The reconstruction used a bipedicled groin and latissimus dorsi flap, with composite rib autologous reconstruction. The patient successfully recovered from the operation. Our case illustrates the applicability of this flap in the armamentarium of anterior chest wall reconstructive options.
Aberrant lipid metabolism as a therapeutic target in liver cancer
Pope, Evans D. , Kimbrough, ErinMarie O. , Vemireddy, Lalitha Padmanabha, Surapaneni, Phani Keerthi, Copland, John A. , Mody, Kabir

Mayo Clinic

Expert Opinion on Therapeutic Targets | May 11, 2019 | Volume: 23 | Issue: 6 | Pages: 473-483

10.1080/14728222.2019.1615883 | PMID 31076001 Get It

Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions
Reddy, Yogesh N.V. , Borlaug, Barry A. , O’Connor, Christopher M. , Nishimura, Rick , Borlaug, Barry A , Gersh, Bernard J.

Mayo Clinic

European Heart Journal | May 10, 2019 | Volume: 41 | Issue: 18 | Pages: 1764-1774

10.1093/eurheartj/ehz364 | PMID 31199474 Get It

Abstract Despite improvements in outcomes in the last few decades for heart failure (HF) with reduced ejection fraction (HFrEF), there still remains a need for novel therapies as many patients incompletely recover with existing therapies and progress to advanced HF. In this review, we will discuss recent advances in the management of HFrEF with a focus on upcoming therapies that hold the greatest promise for clinical use. We will discuss novel pharmacological therapies and areas of uncertainty with existing therapies. We will also discuss the potential utility and controversy surrounding novel interventions for HF such as percutaneous mitral valve repair, atrial fibrillation ablation, and other emerging interventions with positive signals for benefit in HFrEF. Finally, we will summarize the current state of stem cell and gene therapy for HFrEF and future directions.
Leaky gut: mechanisms, measurement and clinical implications in humans
Camilleri, Michael

Mayo Clinic

Gut | May 10, 2019 | Volume: 68 | Issue: 8 | Pages: 1516-1526

10.1136/gutjnl-2019-318427 | PMID 31076401 Get It

The objectives of this review on ‘leaky gut’ for clinicians are to discuss the components of the intestinal barrier, the diverse measurements of intestinal permeability, their perturbation in non-inflammatory ‘stressed states’ and the impact of treatment with dietary factors. Information on ‘healthy’ or ‘leaky’ gut in the public domain requires confirmation before endorsing dietary exclusions, replacement with non-irritating foods (such as fermented foods) or use of supplements to repair the damage. The intestinal barrier includes surface mucus, epithelial layer and immune defences. Epithelial permeability results from increased paracellular transport, apoptosis or transcellular permeability. Barrier function can be tested in vivo using orally administered probe molecules or in vitro using mucosal biopsies from humans, exposing the colonic mucosa from rats or mice or cell layers to extracts of colonic mucosa or stool from human patients. Assessment of intestinal barrier requires measurements beyond the epithelial layer. ‘Stress’ disorders such as endurance exercise, non-steroidal anti-inflammatory drugs administration, pregnancy and surfactants (such as bile acids and dietary factors such as emulsifiers) increase permeability. Dietary factors can reverse intestinal leakiness and mucosal damage in the ‘stress’ disorders. Whereas inflammatory or ulcerating intestinal diseases result in leaky gut, no such disease can be cured by simply normalising intestinal barrier function. It is still unproven that restoring barrier function can ameliorate clinical manifestations in GI or systemic diseases. Clinicians should be aware of the potential of barrier dysfunction in GI diseases and of the barrier as a target for future therapy.
Reply to “Supporting Family Physician Maternity Care Providers”
Goldstein, Jessica Taylor , Hartman, Scott, Meunier, Matthew R. , Panchal, Bethany, Pecci, Christine Chang , Zink, Nancy M., Shields, Sara G.

Mayo Clinic

Family Medicine | May 10, 2019 | Volume: 51 | Issue: 5 | Pages: 447-447

10.22454/fammed.2019.119002 | PMID 31081923 Get It

Short-term Calorie Restriction and 17α-Estradiol Administration Elicit Divergent Effects on Proteostatic Processes and Protein Content in Metabolically Active Tissues
Miller, Benjamin F. , Pharaoh, Gavin , Hamilton, Karyn L. , Peelor, Fredrick F., Kirkland, James L. , Freeman, Willard M. , Mann, Shivani N. , Price, John C. , Freeman, Willard M , Kinter, Michael T , Stout, Michael B

Mayo Clinic

The Journals of Gerontology: Series A | May 10, 2019 | Volume: 75 | Issue: 5 | Pages: 849-857

10.1093/gerona/glz113 | PMID 31074767 Get It

Abstract17α-Estradiol (17α-E2) is a “non-feminizing” estrogen that extends life span in male, but not female, mice. We recently reported that 17α-E2 had robust beneficial effects on metabolic and inflammatory parameters in aged male mice. However, it remains unclear if 17α-E2 also delays other “hallmarks” of aging, particularly maintaining proteostasis. Here, we used isotope labeling methods in older mice to examine proteostatic mechanisms. We compared weight-matched mild calorie restricted (CR) and 17α-E2 treated male mice with the hypothesis that 17α-E2 would increase protein synthesis for somatic maintenance. 17α-E2 had no effect on protein synthesis or DNA synthesis in multiple tissues, including white adipose tissue. Conversely, mild short-term CR decreased DNA synthesis and increased the protein to DNA synthesis ratio in multiple tissues. Examination of individual protein synthesis and content did not differentiate treatments, although it provided insight into the regulation of protein content between tissues. Contrary to our hypothesis, we did not see the predicted differences in protein to DNA synthesis following 17α-E2 treatment. However, mild short-term CR elicited differences consistent with both lifelong CR and other treatments that curtail aging processes. These data indicated that despite similar maintenance of body mass, 17α-E2 and CR treatments elicit distinctly different proteostatic outcomes.